European Medicines Committee Backs Johnson & Johnson's COVID-19 Booster Dose - Johnson & Johnson (NYSE:JNJ), Moderna (NASDAQ:MRNA), Pfizer (NYSE:PFE), BioNTech (NASDAQ:BNTX)

EMA's human medicines committee (CHMP) has concluded that a booster dose of Johnson & Johnson's PFE COVID-19 vaccine may be considered at least two months after the first dose in people aged 18 years and above.
The recommendation follows data showing that a booster dose of COVID-19 vaccine given at least two months after the first dose in adults led to a rise in antibodies against SARS-CoV-2.
The risk of thrombosis combined with thrombocytopenia (TTS) or other very rare side effects after a booster is not known and is being carefully monitored.
CHMP also concluded that a booster dose with COVID-19 vaccine might be given after two doses of one of the mRNA vaccines authorized in the EU, Comirnaty, from Pfizer Inc PFE / BioNTech SE BNTX or Spikevax, from Moderna Inc MRNA.
Related Link: Johnson & Johnson Booster COVID-19 Shot Shows Encouraging Action After Pfizer/BioNTech Jab.
Price Action: JNJ shares are up 0.19% at $170.62 during the market session on the last check Wednesday.